In real-world practice, oncologists are granting treatment breaks, or 'holidays,' to metastatic bladder cancer patients who achieve major responses on enfortumab vedotin-pembrolizumab. This practice, driven by toxicity management and quality of life concerns, is common despite the lack of formal trial data to guide the optimal duration or timing of discontinuation.

For the typically young and active desmoid tumor patient population, the convenience of a once-daily oral pill is a major advantage. This seemingly simple feature significantly improves compliance and adherence compared to twice-daily regimens, making it a key factor in real-world treatment feasibility and success, more so than the specific milligram dosage.

After years of treatment intensification, a new focus in metastatic hormone-sensitive prostate cancer is de-escalation. Trials like ADREAM are evaluating planned treatment interruptions for patients with excellent responses, aiming to provide 'treatment-free intervals' that improve quality of life without sacrificing efficacy.

Even when desmoid tumor patients seem to tolerate niragacestat well, they often report a surprising improvement in well-being after discontinuing the drug. This reveals a subtle, cumulative quality-of-life impact from low-grade toxicities that may not be fully appreciated by patients or clinicians during active treatment.

As more effective treatments for desmoid tumors become available, a critical unmet need is emerging: knowing when to stop therapy. Future research must focus on identifying signals, such as radiologic changes on MRI, to guide treatment duration. This will help clinicians avoid both the risk of early relapse from stopping too soon and the toxicity of unnecessary overtreatment.

For desmoid tumors, systemic therapy is typically paused after 1 to 1.5 years once the tumor stabilizes and stops shrinking. Unlike many other treatments, it can be stopped abruptly without needing to taper the dose, simplifying the discontinuation process for patients and clinicians.

Desmoid tumors exhibit highly variable behavior, acting as a chronic disease in some patients while being manageable in others. This necessitates a personalized, long-term treatment strategy rather than a standard protocol, often requiring a diverse armamentarium of therapeutic options to be used over a patient's lifetime as needs change.

While new systemic treatments for desmoid tumors can effectively control the disease and improve quality of life by managing symptoms, they introduce their own set of side effects. This creates a clinical challenge where the positive impact on the tumor must be carefully weighed against the negative impact of the treatment itself on the patient's daily life.

While continuous therapy remains the official standard of care for mHSPC, there's a growing consensus for individualized de-intensification. For patients with a sustained, undetectable PSA (e.g., for two years), clinicians are increasingly comfortable discussing stopping all treatments to improve quality of life and reduce toxicity.